AstraZeneca PLC (AZN)vsSotera Health Co (SHC)
AZN
AstraZeneca PLC
$168.10
+0.16%
HEALTHCARE · Cap: $257.57B
SHC
Sotera Health Co
$18.69
-0.05%
HEALTHCARE · Cap: $5.34B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 4946% more annual revenue ($61.37B vs $1.22B). AZN leads profitability with a 17.0% profit margin vs 13.4%. AZN appears more attractively valued with a PEG of 1.19. SHC earns a higher WallStSmart Score of 66/100 (B-).
AZN
Buy60
out of 100
Grade: C+
SHC
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+15.2%
Fair Value
$195.81
Current Price
$168.10
$27.71 discount
Intrinsic value data unavailable for SHC.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Strong operational efficiency at 38.0%
Earnings expanding 570.0% YoY
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
Expensive relative to growth rate
Premium valuation, high expectations priced in
Trading at 8.0x book value
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.19 suggests the stock is reasonably priced for its growth.
Bull Case : SHC
The strongest argument for SHC centers on Operating Margin, EPS Growth.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : SHC
The primary concerns for SHC are PEG Ratio, P/E Ratio, Price/Book. Debt-to-equity of 3.41 is elevated, increasing financial risk.
Key Dynamics to Monitor
AZN profiles as a mature stock while SHC is a value play — different risk/reward profiles.
SHC carries more volatility with a beta of 1.78 — expect wider price swings.
SHC is growing revenue faster at 9.2% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
SHC scores higher overall (66/100 vs 60/100). AZN offers better value entry with a 15.2% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Sotera Health Co
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Sotera Health Company provides sterilization, laboratory testing, and advisory services to the medical device, pharmaceutical, and food industries in the Americas, Europe, and Asia. The company is headquartered in Broadview Heights, Ohio.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?